# A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

> **NCT07040228** · PHASE1,PHASE2 · RECRUITING · sponsor: **Junjie Hang** · enrollment: 23 (estimated)

## Conditions studied

- Pancreatic Cancer Metastatic

## Interventions

- **DRUG:** Regorafenib combined with Toripalimab and Albumin paclitaxel

## Key facts

- **NCT ID:** NCT07040228
- **Lead sponsor:** Junjie Hang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-26
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07040228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07040228, "A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07040228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*